News coverage about Xencor (NASDAQ:XNCR) has been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Xencor earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.6214471220755 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Xencor (XNCR) Stock Rating Reaffirmed by Cantor Fitzgerald (americanbankingnews.com)
- Xencor (XNCR) Given Outperform Rating at Leerink Swann (americanbankingnews.com)
- Xencor Inc (XNCR) Expected to Earn Q1 2018 Earnings of ($0.55) Per Share (americanbankingnews.com)
- Xencor (XNCR) Rating Increased to Buy at BidaskClub (americanbankingnews.com)
- Xencor (XNCR) Receives Overweight Rating from Cantor Fitzgerald (americanbankingnews.com)
Xencor stock opened at $29.98 on Friday. The stock has a market capitalization of $1,548.71, a price-to-earnings ratio of -28.83 and a beta of 1.50. Xencor has a twelve month low of $18.55 and a twelve month high of $34.63.
Several equities research analysts have commented on the stock. BidaskClub raised shares of Xencor from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 9th. Zacks Investment Research cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Thursday, March 8th. Wedbush upped their target price on shares of Xencor from $38.00 to $39.00 and gave the company an “outperform” rating in a report on Monday, March 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $37.00 target price on shares of Xencor in a report on Thursday, March 1st. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Xencor in a report on Wednesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $36.60.
In related news, insider Paul A. Foster sold 10,000 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $26.03, for a total transaction of $260,300.00. Following the sale, the insider now owns 12,419 shares in the company, valued at approximately $323,266.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Paul A. Foster sold 5,000 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.01, for a total transaction of $125,050.00. Following the sale, the insider now owns 7,419 shares in the company, valued at approximately $185,549.19. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,000 shares of company stock worth $3,101,550. Company insiders own 4.03% of the company’s stock.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.